Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Completed 4Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 62Other hematologic neoplasm 52Myeloid 17Sarcoma 9Plasma cell 6Breast 6Genitourinary 5Classical hematology 5Dermatologic 4Gastrointestinal 2CNS 2Other neoplasm 1Other 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Methotrexate × Gynecologic × Clear all
NCT01175772 2015-06-23

Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

HaEmek Medical Center, Israel

Phase 2 Terminated
6 enrolled
Gynecologic

Carcinoma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡